GlaxoSmithKline is paying out $7.5 million to partner Isis Pharmaceuticals as an antisense drug being developed for transthyretin amyloidosis, "a severe and rare genetic disease," goes into a Phase II/III study.
TTR amyloidosis is characterised by progressive dysfunction of peripheral nerve and/or heart tissues and affects 50,000 patients worldwide and current treatments are limited. The 15-month study of the drug, known as ISIS-TTRRx, will involve some 200 patients with familial amyloid polyneuropathy who experience TTR build-up in their peripheral nerves and experience the loss of motor functions, such as walking.
Lynne Parshall, chief operating officer at Isis, said that "the rapid development of ISIS-TTRRx from a research-stage programme to a drug in late-stage clinical development in just over two years represents the strong commitment of both teams". She added that the encouraging data from a Phase I study, "in which our drug was well tolerated and produced significant reductions in TTR protein, supported the advancement of ISIS-TTRRx directly into this registration-directed Phase II/III study".
The drug is part of an Isis-GSK strategic alliance to develop RNA therapeutics for rare and infectious diseases. That pact was recently amended and apart from the $7.5 million fee, Isis is eligible to earn an additional $50 million to support the study, plus regulatory and sales milestone payments, plus double-digit royalties.
COPD combo accepted for US review
Meantime, GSK and partner Theravance have confirmed that the New Drug Application for their new once-daily chronic obstructive pulmonary disease combination therapy Anoro has been accepted for review by the US Food and Drug Administration.
The drug is a combination of two investigational molecules - GSK573719 or umeclidinium bromide, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2 agonist (LABA), administered using the Ellipta inhaler. The Prescription Drug User Fee Act goal date has also been confirmed as December 18, 2013.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.